September 09, 2024

Max Planck Institute for Medical Research

Max Planck Institute for Medical Research
Go back

Our latest News

discover more
The University Hospital Cologne (UHC), in collaboration with the German Center for Infection Research (DZIF) has selected the Celonic Group for process development and GMP manufacturing of a monoclonal antibody targeting Pseudomonas aeruginosa.

The University Hospital Cologne (UHC), in collaboration with the German Center for Infection Research (DZIF) has selected the Celonic Group for process development and GMP manufacturing of a monoclonal antibody targeting Pseudomonas aeruginosa.

Basel, Switzerland / Köln, Germany August 12, 2026 The University Hospital Cologne (Universitätsklinikum Köln, UHC) has chosen the Celonic Group as its CDMO partner for advanced process development and GMP manufacturing of its monoclonal antibody targeting Pseudomonas aeruginosa, a Gram‑negative pathogen responsible for severe hospital‑acquired infections, biofilm‑driven persistence, and rising antimicrobial resistance. The antibody program is […]

read more
Combating the pandemic: Diagnostic chips ten times more sensitive

Combating the pandemic: Diagnostic chips ten times more sensitive

A team at KIT has developed a solution that significantly improves novel biosensors for medical use and enables faster diagnosis of infectious diseases Rapid, straightforward and, at the same time, accurate diagnosis of highly contagious pathogens such as the SARS-CoV-2 virus, which caused the coronavirus pandemic, is crucial to curbing the spread of disease. This […]

read more
Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding

Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding

Joint Press Release from NCT Heidelberg and Mannheim University Medical Center The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium. […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp